argenex SE (NASDAQ:ARGX – Free Report) – Stock analysts at HC Wainwright lifted their FY2027 EPS estimates for shares of argenex in a research note issued to investors on Tuesday, August 18th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of $34.82 per share for the year, up from their previous forecast of $34.38. HC Wainwright has a “Buy” rating and a $1,202.00 price objective on the stock. The consensus estimate for argenex’s current full-year earnings is $28.77 per share. HC Wainwright also issued estimates for argenex’s FY2028 earnings at $44.72 EPS.
argenex (NASDAQ:ARGX – Get Free Report) last issued its earnings results on Tuesday, July 21st. The company reported $7.32 EPS for the quarter, beating analysts’ consensus estimates of $5.86 by $1.46. The business had revenue of $1.54 billion during the quarter, compared to analysts’ expectations of $1.45 billion. argenex had a net margin of 32.19% and a return on equity of 43.59%.
View Our Latest Analysis on argenex
argenex Trading Up 0.5%
ARGX stock opened at $992.99 on Wednesday. The firm has a 50-day moving average of $886.02 and a two-hundred day moving average of $823.02. argenex has a 12 month low of $650.01 and a 12 month high of $1,009.75. The company has a market cap of $62.12 billion, a price-to-earnings ratio of 38.13, a PEG ratio of 1.05 and a beta of 0.46.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC raised its holdings in argenex by 3.4% during the first quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock worth $1,847,592,000 after purchasing an additional 83,568 shares in the last quarter. M&T Bank Corp lifted its stake in argenex by 20,977.7% in the fourth quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock valued at $654,772,000 after buying an additional 774,916 shares during the last quarter. Wellington Management Group LLP grew its position in shares of argenex by 80.1% during the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after acquiring an additional 324,653 shares during the last quarter. Morgan Stanley boosted its stake in argenex by 19.2% during the 4th quarter. Morgan Stanley now owns 518,852 shares of the company’s stock worth $436,331,000 after purchasing an additional 83,746 shares during the period. Finally, Invesco Ltd. increased its stake in argenex by 390.4% in the fourth quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock valued at $350,178,000 after purchasing an additional 331,489 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.
argenex News Summary
Here are the key news stories impacting argenex this week:
- Positive Sentiment: argenx reported that its Phase 3 ALKIVIA trial of Vyvgart Hytrulo met its primary endpoint in autoimmune myositis. The result supports a potential label expansion for the drug and was followed by a sharp increase in the shares. ARGX Announces Positive Phase III Data on Vyvgart Hytrulo
- Positive Sentiment: Morgan Stanley said the myositis data strengthen the outlook for efgartigimod, the active ingredient in Vyvgart, and raised its price target for argenex SE from $1,200 to $1,230 while maintaining an “overweight” rating. Argenx’s Myositis Data Strengthen Efgartigimod Outlook
- Positive Sentiment: Several firms lifted their targets after the trial update: Piper Sandler to $1,215, Wedbush to $1,150, RBC to $1,100, Truist to $1,095, HC Wainwright to $1,202 and Citizens JMP to $1,200. The upgrades generally retained bullish ratings, signaling greater expected upside and confidence in the commercial opportunity.
- Positive Sentiment: The analyst optimism helped ARGX hit a new 52-week high, with the stock opening near $993 versus a prior 52-week high of $1,009.75. argenex Hits New 1-Year High Following Analyst Upgrade
- Neutral Sentiment: Investors will likely focus next on regulatory and commercialization milestones for the myositis indication. Although analyst targets imply further upside, ARGX already trades near its 52-week high, making execution and valuation important considerations.
argenex Company Profile
argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.
The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.
Featured Stories
- Five stocks we like better than argenex
- Amazon Plugs $18B Into the Southern Power Grid
- Speed Sells: Cerebras Cracks the Silicon Ceiling
- Amid Legal Risks, This Company Is Still Rated a Buy
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
